Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma

Cancer Research

Volumn 70, Issue 9, 2010, Pages 3791-3802

  Muth, Daniel ^a   Ghazaryan, Seda ^a   Eckerle, Isabella ^a   Beckett, Emily ^a   Pöhler, Christina ^a   Batzler, Julia ^a   Beisel, Claudia ^b   Gogolin, Sina ^a   Fischer, Matthias ^b   Henrich, Kai Oliver ^a   Ehemann, Volker ^a   Gillespie, Paul ^c   Schwab, Manfred ^a   Westermann, Frank ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; DOXORUBICIN; MYCN PROTEIN; NUTLIN 3; PRB PROTEIN; PROTEIN; PROTEIN P21; PROTEIN P53; S PHASE KINASE ASSOCIATED PROTEIN 2; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR ELK 1; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME INDUCTION; ENZYME INHIBITION; GENE ACTIVATION; GENE AMPLIFICATION; GENE CONTROL; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MITOGENESIS; NEUROBLASTOMA; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 4; E2F1 TRANSCRIPTION FACTOR; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROMOTER REGIONS, GENETIC; RETINOBLASTOMA PROTEIN; RNA, MESSENGER; S-PHASE KINASE-ASSOCIATED PROTEINS; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION, GENETIC;

EID: 77951749646     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1245     Document Type: Article

References (33)

1. Zheng N, Schulman BA, Song L, et al. Structure of the Cul1-1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 2002;416:703-709
2. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003;13:41-47
3. Pagano M, Benmaamar R. When protein destruction runs amok, malignancy is on the loose. Cancer Cell 2003;4:251-256
4. Zhang L, Wang C. F-box protein Skp2:a novel transcriptional target of E2F. Oncogene 2006;25:2615-2627
5. Yung Y, Walker JL, Roberts JM, Assoian RK. A Skp2 autoinduction loop and restriction point control. J Cell Biol 2007;178:741-747
6. Westermann F, Henrich KO, Wei JS, et al. High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status. Clin Cancer Res 2007;13:4695-4703
7. Kramps C, Strieder V, Sapetschnig A, Suske G, Lutz W. E2F and Sp1/Sp3 Synergize but are not sufficient to activate the MYCN gene in neuroblastomas. J Biol Chem 2004;279:5110-5117
8. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of α-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996;13:803-812
9. van de Wetering M, Oving I, Muncan V, et al. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep 2003;4:609-615
10. Oberthuer A, Berthold F, Warnat P, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006;24:5070-5078
11. SagulenkoV,MuthD,Sagulenko E, Paffhausen T, Schwab M, Westermann F. Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death. Carcinogenesis 2008;29:1869-1877
12. Deubzer HE, Ehemann V, Westermann F, et al. Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells. Int J Cancer 2008;122:1891-1900
13. Wiedemeyer R, Westermann F, Wittke I, Nowock J, SchwabM. Ataxin-2 promotes apoptosis of human neuroblastoma cells. Oncogene 2003;22:401-411
14. Henrich KO, Fischer M, Mertens D, et al. Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients. Clin Cancer Res 2006;12:131-138
15. Westermann F, Muth D, Benner A, et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 2008;9:R150.
16. Frank SR, Schroeder M, Fernandez P, Taubert S, Amati B. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev 2001;15:2069-2082
17. Nowak K, Kerl K, Fehr D, et al. BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res 2006;34:1745-1754
18. Hernando E, Nahle Z, Juan G, et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 2004;430:797-802.
19. Appleman LJ, Chernova I, Li L, Boussiotis VA. CD28 costimulation mediates transcription of SKP2 and CKS1, the substrate recognition components of SCFSkp2 ubiquitin ligase that leads p27kip1 to degradation. Cell Cycle 2006;5:2123-2129 (Pubitemid 44553747)
20. Cartharius K, Frech K, Grote K, et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005;21:2933-2942 (Pubitemid 40916416)
21. Imaki H, Nakayama K, Delehouzee S, et al. Cell cycle-dependent regulation of the Skp2 promoter by GA-binding protein. Cancer Res 2003;63:4607-4613 (Pubitemid 36951037)
22. Cobrinik D. Pocket proteins and cell cycle control. Oncogene 2005;24:2796-2809 (Pubitemid 40638091)
23. Vogan K, Bernstein M, Leclerc JM, et al. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res 1993;53:5269-5273 (Pubitemid 23333398)
24. Ohtani K, DeGregori J, Nevins JR. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci U S A 1995;92:12146-12150 (Pubitemid 26014027)
25. Radhakrishnan SK, Feliciano CS, Najmabadi F, et al. Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle. Oncogene 2004;23:4173-4176 (Pubitemid 38747949)
26. Wang C, Hou X, Mohapatra S, et al. Activation of p27Kip1 expression by E2F1. A negative feedback mechanism. J Biol Chem 2005;280:12339-12343 (Pubitemid 40491047)
27. Ji P, Jiang H, Rekhtman K, et al. An Rb-Skp2-27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant. Mol Cell 2004;16:47-58. (Pubitemid 39330151)
28. Eckerle I, Muth D, Batzler J, et al. Regulation of BIRC5 and its isoform BIRC5-2B in neuroblastoma. Cancer Lett 2009;285:99-107.
29. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-741
30. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (New York, NY) 2004;303:844-848
31. Burgess A, Wigan M, Giles N, et al. Inhibition of S/G2 phase CDK4 reduces mitotic fidelity. J Biol Chem 2006;281:9987-9995 (Pubitemid 43864531)
32. Kitagawa M, Higashi H, Jung HK, et al. The consensus motif for phosphorylation by cyclin D1-4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J 1996;15:7060-7069
33. Chong JL, Wenzel PL, Saenz-Robles MT, et al. E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells. Nature 2009;462:930-934